<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Seed</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Tippingpoint raises seed financing to target epigenetic protein interfaces</title>
      <description>
        <![CDATA[Tippingpoint Biosciences Inc. has closed an oversubscribed $4.5 million seed financing. The company, spun out of a lab at University of California, San Francisco (UCSF), is advancing its novel drug discovery platform designed to identify first-in-class drugs to treat diseases related to dysfunctional DNA packaging (chromatin).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730061</guid>
      <pubDate>Wed, 01 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730061-tippingpoint-raises-seed-financing-to-target-epigenetic-protein-interfaces</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Chromatin-compaction.webp?t=1775055876" type="image/jpeg" medium="image" fileSize="405741">
        <media:title type="plain">Chromatin compaction</media:title>
      </media:content>
    </item>
    <item>
      <title>Idel raises $10.4M for intracellular pan-cancer drug delivery tech</title>
      <description>
        <![CDATA[Newco Idel Therapeutics GmbH has closed a €9 million (US$10.4 million) seed round to advance the development of a technology for delivery of cytotoxic drugs directly into the cytosol of tumor cells.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729904</guid>
      <pubDate>Thu, 26 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729904-idel-raises-104m-for-intracellular-pan-cancer-drug-delivery-tech</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cell-under-magnifying-glass.webp?t=1611092780" type="image/png" medium="image" fileSize="453785">
        <media:title type="plain">Cancer cells under magnifying glass</media:title>
      </media:content>
    </item>
    <item>
      <title>Rybodyn raises funding to decode the dark proteome</title>
      <description>
        <![CDATA[Rybodyn Inc. has announced the initial close of a $10 million seed financing to support its work decoding the dark proteome using an AI-powered novel sequencing and discovery platform. The financing will accelerate the company’s transition from foundational discovery into scaled platform execution and progress early-stage programs into IND-enabling studies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729878</guid>
      <pubDate>Wed, 25 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729878-rybodyn-raises-funding-to-decode-the-dark-proteome</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Health-research-body-molecules.webp?t=1743605757" type="image/jpeg" medium="image" fileSize="735256">
        <media:title type="plain">Art concept for medical research</media:title>
      </media:content>
    </item>
    <item>
      <title>Excalipoint closes $68.7M seed round for cancer T-cell engagers </title>
      <description>
        <![CDATA[Excalipoint Therapeutics Inc. launched with an oversubscribed $68.7 million seed financing round to advance a portfolio of T-cell engagers for solid tumors, marking one of the largest early stage financings in China biotech history.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729898</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729898-excalipoint-closes-687m-seed-round-for-cancer-t-cell-engagers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Blue-gray-dollar-sign.webp?t=1773864630" type="image/jpeg" medium="image" fileSize="944348">
        <media:title type="plain">Blue-gray dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Laigo extends seed round as targeted protein degradation field gathers pace</title>
      <description>
        <![CDATA[Laigo Bio BV has extended its seed round to €17 million (US$19.8 million), after making progress with translating its novel E3 ubiquitin ligase targeted protein degradation technology toward the clinic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729812</guid>
      <pubDate>Mon, 23 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729812-laigo-extends-seed-round-as-targeted-protein-degradation-field-gathers-pace</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Euro-currency-symbol-white.webp?t=1669153720" type="image/png" medium="image" fileSize="307769">
        <media:title type="plain">White Euro symbol on blue background</media:title>
      </media:content>
    </item>
    <item>
      <title>Excalipoint closes $68.7M seed round for cancer T-cell engagers </title>
      <description>
        <![CDATA[Excalipoint Therapeutics Inc. launched with an oversubscribed $68.7 million seed financing round to advance a portfolio of T-cell engagers for solid tumors, marking one of the largest early stage financings in China biotech history.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729788</guid>
      <pubDate>Thu, 19 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729788-excalipoint-closes-687m-seed-round-for-cancer-t-cell-engagers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Blue-gray-dollar-sign.webp?t=1773864630" type="image/jpeg" medium="image" fileSize="944348">
        <media:title type="plain">Blue-gray dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Excalipoint closes $68.7M seed round for cancer T-cell engagers </title>
      <description>
        <![CDATA[Excalipoint Therapeutics Inc. launched with an oversubscribed $68.7 million seed financing round to advance a portfolio of T-cell engagers for solid tumors, marking one of the largest early stage financings in China biotech history.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729560</guid>
      <pubDate>Wed, 18 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729560-excalipoint-closes-687m-seed-round-for-cancer-t-cell-engagers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Blue-gray-dollar-sign.webp?t=1773864630" type="image/jpeg" medium="image" fileSize="944348">
        <media:title type="plain">Blue-gray dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Enodia jumps ahead in Sec61 targeting, adds Kezar’s program</title>
      <description>
        <![CDATA[Enodia Therapeutics Inc. was spun out of The Institut Pasteur by Argobio Studio based on the work of Caroline Demangel, co-founder of Enodia and head of the immunobiology and therapy unit at The Institut Pasteur. Demangel’s lab discovered the mechanism of action of mycolactone, a natural Sec61 inhibitor that causes Buruli ulcers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729706</guid>
      <pubDate>Tue, 17 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729706-enodia-jumps-ahead-in-sec61-targeting-adds-kezars-program</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Tinted-Euro-symbol.webp?t=1685996236" type="image/jpeg" medium="image" fileSize="59509">
        <media:title type="plain">Tinted Euro symbol</media:title>
      </media:content>
    </item>
    <item>
      <title>Enodia jumps ahead in Sec61 targeting, adds Kezar’s program</title>
      <description>
        <![CDATA[Enodia Therapeutics Inc. was spun out of The Institut Pasteur by Argobio Studio based on the work of Caroline Demangel, co-founder of Enodia and head of the immunobiology and therapy unit at The Institut Pasteur. Demangel’s lab discovered the mechanism of action of mycolactone, a natural Sec61 inhibitor that causes Buruli ulcers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729529</guid>
      <pubDate>Mon, 16 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729529-enodia-jumps-ahead-in-sec61-targeting-adds-kezars-program</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Tinted-Euro-symbol.webp?t=1685996236" type="image/jpeg" medium="image" fileSize="59509">
        <media:title type="plain">Tinted Euro symbol</media:title>
      </media:content>
    </item>
    <item>
      <title>Financing at Gelmedix supports GMX-101 for geographic atrophy</title>
      <description>
        <![CDATA[Gelmedix Inc. has completed a $13 million seed financing to support progression of the company’s lead program, GMX-101, a retinal pigment epithelial (RPE) cell therapy to treat late-stage geographic atrophy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728920</guid>
      <pubDate>Wed, 18 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728920-financing-at-gelmedix-supports-gmx-101-for-geographic-atrophy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RD-money.webp?t=1588877677" type="image/png" medium="image" fileSize="578436">
        <media:title type="plain">Dollar sign droplet above test tube</media:title>
      </media:content>
    </item>
    <item>
      <title>ALTx formed to drug pathway by which cancer cells become immortal </title>
      <description>
        <![CDATA[Newco ALTx Therapeutics Ltd. has launched with a £12.55 million (US$17.1 million) seed round to develop inhibitors of the alternative lengthening of telomeres (ALT) pathway, by which 10% to 15% of cancers become immortal.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728760</guid>
      <pubDate>Fri, 06 Feb 2026 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728760-altx-formed-to-drug-pathway-by-which-cancer-cells-become-immortal</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Chromosome-with-shortened-telomeres.webp?t=1675437576" type="image/png" medium="image" fileSize="336105">
        <media:title type="plain">Chromosome with shortened telomeres</media:title>
      </media:content>
    </item>
    <item>
      <title>ALTx formed to drug pathway by which cancer cells become immortal </title>
      <description>
        <![CDATA[Newco ALTx Therapeutics Ltd. has launched with a £12.55 million (US$17.1 million) seed round to develop inhibitors of the alternative lengthening of telomeres (ALT) pathway, by which 10% to 15% of cancers become immortal.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728645</guid>
      <pubDate>Thu, 05 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728645-altx-formed-to-drug-pathway-by-which-cancer-cells-become-immortal</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Chromosome-with-shortened-telomeres.webp?t=1675437576" type="image/png" medium="image" fileSize="336105">
        <media:title type="plain">Chromosome with shortened telomeres</media:title>
      </media:content>
    </item>
    <item>
      <title>Seed funding at Enodia for targeted protein degradation platform</title>
      <description>
        <![CDATA[Enodia Therapeutics SAS has raised €20.7 million ($25 million) in seed financing to advance its work developing novel small-molecule therapies for targeted protein degradation at the point of synthesis. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/727914</guid>
      <pubDate>Mon, 12 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727914-seed-funding-at-enodia-for-targeted-protein-degradation-platform</link>
    </item>
    <item>
      <title>Shanx secures €15M to accelerate rapid antimicrobial testing</title>
      <description>
        <![CDATA[Shanx Medtech BV raised €15 million (US$17.5 million) in a seed funding round for its in vitro diagnostic platform for ultra-rapid antimicrobial susceptibility testing. The financing came from a range of sources including equity, grants and a loan, and will be used to accelerate the development, clinical validation, regulatory approval, and commercial launch of the diagnostic platform.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727586</guid>
      <pubDate>Wed, 07 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727586-shanx-secures-15m-to-accelerate-rapid-antimicrobial-testing</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2026/Shanx-Medtech-7jan26.webp?t=1767825380" type="image/jpeg" medium="image" fileSize="113745">
        <media:title type="plain">Shanx Medtech IVD</media:title>
        <media:description type="plain">Shanx Medtech in vitro diagnostic platform for ultra-rapid antimicrobial susceptibility testing. Credit: Shanx Medtech BV</media:description>
      </media:content>
    </item>
    <item>
      <title>Laigo raises €11.5M seed money for targeted protein degradation </title>
      <description>
        <![CDATA[Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by E3 ubiquitin ligases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726926</guid>
      <pubDate>Fri, 05 Dec 2025 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726926-laigo-raises-115m-seed-money-for-targeted-protein-degradation</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/3D-Euro-sign.webp?t=1594242852" type="image/png" medium="image" fileSize="325384">
        <media:title type="plain">3D Euro symbol</media:title>
      </media:content>
    </item>
    <item>
      <title>Laigo raises €11.5M seed money for targeted protein degradation </title>
      <description>
        <![CDATA[Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by E3 ubiquitin ligases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726817</guid>
      <pubDate>Thu, 04 Dec 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726817-laigo-raises-115m-seed-money-for-targeted-protein-degradation</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/3D-Euro-sign.webp?t=1594242852" type="image/png" medium="image" fileSize="325384">
        <media:title type="plain">3D Euro symbol</media:title>
      </media:content>
    </item>
    <item>
      <title>Junevity raises funds to advance siRNA metabolism program</title>
      <description>
        <![CDATA[Junevity Inc. has raised $10 million in new funding, bringing its seed financing to a total of $20 million. The new funding will enable Junevity to advance JUN-01, its lead siRNA program for type 2 diabetes and obesity, through IND-enabling and initial clinical studies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726804</guid>
      <pubDate>Thu, 04 Dec 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726804-junevity-raises-funds-to-advance-sirna-metabolism-program</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Endocrine-Metabolic-glucose-bloodstream.webp?t=1674056639" type="image/png" medium="image" fileSize="1313266">
        <media:title type="plain">Illustration of glucose molecules in a bloodstream</media:title>
      </media:content>
    </item>
    <item>
      <title>Customed raises funds for platform to transform orthopedic surgery</title>
      <description>
        <![CDATA[Customed Ltd. has completed its seed funding round, bringing the total capital raised to $6 million. The company has developed a platform which provides orthopedic surgeons with personalized pre-surgical planning and 3D printed surgical tools. The funds will be used to support regulatory approvals in the U.S. and EU, as well as expansion into additional automated orthopedic indications.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725462</guid>
      <pubDate>Thu, 30 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725462-customed-raises-funds-for-platform-to-transform-orthopedic-surgery</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/CustoMED-software-10-30.webp?t=1761859346" type="image/jpeg" medium="image" fileSize="192480">
        <media:title type="plain">Customed software </media:title>
        <media:description type="plain">Customed software provides orthopedic surgeons with personalized pre-surgical planning and 3D printed surgical tools. Credit: Customed Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Seed financing at Cirrus Therapeutics to develop ocular medicines</title>
      <description>
        <![CDATA[Cirrus Therapeutics Inc. has closed an $11 million seed financing to advance its pipeline of gene and cell therapies designed to preserve sight and extend ocular healthspan in patients with chronic blinding diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724747</guid>
      <pubDate>Fri, 03 Oct 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724747-seed-financing-at-cirrus-therapeutics-to-develop-ocular-medicines</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-and-DNA.webp?t=1621374169" type="image/png" medium="image" fileSize="619372">
        <media:title type="plain">Eye and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Immuto Scientific announces financing, Daiichi Sankyo collab</title>
      <description>
        <![CDATA[Immuto Scientific Inc. has closed an $8 million seed 2 financing round and entered into a drug discovery collaboration with Daiichi Sankyo Co. Ltd. Immuto applies its target discovery platform and structural epitope‑mapping engine to identify disease‑specific surface protein conformations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724332</guid>
      <pubDate>Thu, 18 Sep 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724332-immuto-scientific-announces-financing-daiichi-sankyo-collab</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/business-performance-pipeline.webp?t=1588793771" type="image/png" medium="image" fileSize="544180">
        <media:title type="plain">Business pipeline illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Axelyf emerges to tackle RNA delivery, advance autoimmune pipeline</title>
      <description>
        <![CDATA[Partly focused on delivery challenges that have limited the reach of RNA medicines, new biotech company Axelyf Inc. closed a $2.6 million seed round to support development of its AXL technology and to advance lead autoimmune candidate AXL-003.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723626</guid>
      <pubDate>Tue, 26 Aug 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723626-axelyf-emerges-to-tackle-rna-delivery-advance-autoimmune-pipeline</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RNA-3D-illustration.webp?t=1725482193" type="image/jpeg" medium="image" fileSize="212050">
        <media:title type="plain">3D illustration of RNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Axelyf emerges to tackle RNA delivery, advance autoimmune pipeline</title>
      <description>
        <![CDATA[Partly focused on delivery challenges that have limited the reach of RNA medicines, new biotech company Axelyf Inc. closed a $2.6 million seed round to support development of its AXL technology and to advance lead autoimmune candidate AXL-003.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723303</guid>
      <pubDate>Mon, 25 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723303-axelyf-emerges-to-tackle-rna-delivery-advance-autoimmune-pipeline</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RNA-3D-illustration.webp?t=1725482193" type="image/jpeg" medium="image" fileSize="212050">
        <media:title type="plain">3D illustration of RNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Aussie gene therapy company emerges from stealth  </title>
      <description>
        <![CDATA[Aussie gene therapy company Mirugen Pty Ltd. has emerged from stealth mode from the Center for Eye Research Australia in Melbourne, toting a AU$4.5 million (US$2.9 million) seed round that will see it optimize its lead candidate to treat retinitis pigmentosa.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723471</guid>
      <pubDate>Tue, 19 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723471-aussie-gene-therapy-company-emerges-from-stealth</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Mirugen-co-founders-Keith-Martin-(L)-and-Raymond-Wong-(R).webp?t=1755204408" type="image/jpeg" medium="image" fileSize="581360">
        <media:title type="plain">Mirugen co-founders Keith Martin (L) and Raymond Wong (R)</media:title>
        <media:description type="plain">Mirugen co-founders Keith Martin, left, and Raymond Wong. Credit: Anna Carlile</media:description>
      </media:content>
    </item>
    <item>
      <title>Aussie gene therapy company emerges from stealth  </title>
      <description>
        <![CDATA[Aussie gene therapy company Mirugen Pty Ltd. has emerged from stealth mode from the Center for Eye Research Australia in Melbourne, toting a AU$4.5 million (US$2.9 million) seed round that will see it optimize its lead candidate to treat retinitis pigmentosa.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723036</guid>
      <pubDate>Thu, 14 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723036-aussie-gene-therapy-company-emerges-from-stealth</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Mirugen-co-founders-Keith-Martin-(L)-and-Raymond-Wong-(R).webp?t=1755204408" type="image/jpeg" medium="image" fileSize="581360">
        <media:title type="plain">Mirugen co-founders Keith Martin (L) and Raymond Wong (R)</media:title>
        <media:description type="plain">Mirugen co-founders Keith Martin, left, and Raymond Wong. Credit: Anna Carlile</media:description>
      </media:content>
    </item>
    <item>
      <title>Plexāā Bloom43 to transform breast reconstruction surgery</title>
      <description>
        <![CDATA[Plexāā Ltd. recently raised $4.5 million to support the upcoming U.S. launch of Bloom43, its wearable device that helps patients prepare for breast cancer surgery and reconstruction by using a technique called supraphysiological preconditioning.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722080</guid>
      <pubDate>Tue, 22 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722080-plex-bloom43-to-transform-breast-reconstruction-surgery</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Plexaa-Bloom43-22july25.webp?t=1753217166" type="image/jpeg" medium="image" fileSize="87249">
        <media:title type="plain">Plexaa Bloom43</media:title>
        <media:description type="plain">Plexāā Bloom43. Credit: Plexāā Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Renasant launches with $54.5M to develop drugs for a genetic kidney disease</title>
      <description>
        <![CDATA[Launched out of 5AM Ventures’ 4:59 Initiative, Renasant Bio Inc. has secured $54.5 million in seed funding to support development of treatments for autosomal dominant polycystic kidney disease (ADPKD), a genetic disease caused by mutations in the PKD1 and PKD2 genes, which encode polycystin proteins PC1 and PC2 that come together to form a calcium ion channel vital for kidney function.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722151</guid>
      <pubDate>Tue, 15 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722151-renasant-launches-with-545m-to-develop-drugs-for-a-genetic-kidney-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/kidney-genetic-congenital.webp?t=1709655526" type="image/jpeg" medium="image" fileSize="168177">
        <media:title type="plain">Illustration of kidney with DNA structures</media:title>
      </media:content>
    </item>
    <item>
      <title>Abvance Therapeutics secures seed funding to limit glucose lows</title>
      <description>
        <![CDATA[Abvance Therapeutics Inc. secured an undisclosed amount of capital in a seed round led by Zubi Capital to support development of an insulin and glucagon combination product that the company has been in the process of developing for approximately 18 months. “We’re very excited that this round is able to get us positioned for a successful series A once we meet some internal confidential milestones,” Edward Raskin, CEO of Abvance, told <em>BioWorld</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721777</guid>
      <pubDate>Mon, 30 Jun 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721777-abvance-therapeutics-secures-seed-funding-to-limit-glucose-lows</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Newco/newco-plant-dollar-sign.webp?t=1588285768" type="image/png" medium="image" fileSize="378693">
        <media:title type="plain">Hand holding money plant</media:title>
      </media:content>
    </item>
    <item>
      <title>Abvance Therapeutics secures seed funding to limit glucose lows</title>
      <description>
        <![CDATA[Abvance Therapeutics Inc. secured an undisclosed amount of capital in a seed round led by Zubi Capital to support development of an insulin and glucagon combination product that the company has been in the process of developing for approximately 18 months.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721522</guid>
      <pubDate>Thu, 26 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721522-abvance-therapeutics-secures-seed-funding-to-limit-glucose-lows</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Newco/newco-plant-dollar-sign.webp?t=1588285768" type="image/png" medium="image" fileSize="378693">
        <media:title type="plain">Hand holding money plant</media:title>
      </media:content>
    </item>
    <item>
      <title>Startup Elkedonia raises €11M to advance neuroplastogen in depression</title>
      <description>
        <![CDATA[Newco Elkedonia SAS has raised €11 million (US$12.7 million) in a seed round, which will fund it to take a potentially first-in-class ELK-1 inhibitor into the clinic in the treatment of refractory depression. ELK-1 plays a pivotal role in neuroplasticity and in reward circuits in the brain, which when disrupted can lead to depression, addiction and post-traumatic stress disorder.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721347</guid>
      <pubDate>Fri, 13 Jun 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721347-startup-elkedonia-raises-11m-to-advance-neuroplastogen-in-depression</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Psychiatry-illustration.webp?t=1710887261" type="image/jpeg" medium="image" fileSize="103707">
        <media:title type="plain">Two silhouettes with tangle, gear, spiral</media:title>
      </media:content>
    </item>
    <item>
      <title>Startup Elkedonia raises €11M to advance neuroplastogen in depression</title>
      <description>
        <![CDATA[Newco Elkedonia SAS has raised €11 million (US$12.7 million) in a seed round, which will fund it to take a potentially first-in-class ELK-1 inhibitor into the clinic in the treatment of refractory depression. ELK-1 plays a pivotal role in neuroplasticity and in reward circuits in the brain, which when disrupted can lead to depression, addiction and post-traumatic stress disorder.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721077</guid>
      <pubDate>Thu, 12 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721077-startup-elkedonia-raises-11m-to-advance-neuroplastogen-in-depression</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Psychiatry-illustration.webp?t=1710887261" type="image/jpeg" medium="image" fileSize="103707">
        <media:title type="plain">Two silhouettes with tangle, gear, spiral</media:title>
      </media:content>
    </item>
  </channel>
</rss>
